Aripiprazole's Effect on Metabolism in Patients with Behavioral and Psychological Symptoms of Dementia and Correlations between Clinical Efficacy and Blood Concentration

doi:10.19803/j.1672-8629.2021.07.10

Abstract

Abstract: Objective To observe the efficacy of aripiprazole in the treatment of behavioral and psychological symptoms of dementia (BPSD) and its effect on BMI, glucose and lipid metabolism, and explore the correlation between the blood concentration of aripiprazole and clinical efficacy. Methods Thirty patients with BPSD were treated with aripiprazole for 6 weeks. BEHAVE-AD and TESS were used for assessment of the efficacy while BMI, fasting blood glucose (FBS), cholesterol (TC), triglyceride (TG), and high-density lipoprotein (HDL) of the patients were determined. The blood concentration of aripiprazole was determined by HPLC. Results The patients’BEHAVE-AD score decreased significantly after 6 weeks of aripiprazole treatment (P<0.01). BMI, fasting blood glucose, cholesterol, triglyceride, and high-density lipoprotein did not change significantly after treatment. The blood concentrations of aripiprazole at the 4th and 6th weeks of treatment were significantly and positively correlated with the reduction rate of BEHAVE-AD. The blood concentration of the effective group was significantly higher than that of the ineffective group. Conclusion Aripiprazole is effective for BPSD, and has little effect on BMI、glucose or lipid metabolism. It is suitable for patients with cardiovascular and cerebrovascular diseases. There is some correlation between the blood concentration of aripiprazole in the treatment of BPSD and the clinical effect, suggesting that the use of blood concentration as an index can contribute to the efficacy and dose adjustment.

Key words: behavioral and psychological symptoms of dementia, aliprazole, clinical efficacy, glycolipid metabolism, blood drug concentration

CLC Number:

R971.4R969.1

CHENG Xialong, ZHANG Xulai, WU Xiaoping, DAI Biao, WANG Anzhen, YAN Fanfan. Aripiprazole's Effect on Metabolism in Patients with Behavioral and Psychological Symptoms of Dementia and Correlations between Clinical Efficacy and Blood Concentration[J]. Chinese Journal of Pharmacovigilance, 2021, 18(7): 641-644.

References

[1] Liu YM.The status quo, problems and countermeasures of senile dementia in China[J]. China Social Work(中国社会工作), 2018(14): 28-29
[2] Ge GQ, Wang JJ, Tao K, et al.The burden of behavioral and mental symp-toms of patients with Alzheimer's disease on caregivers[J]. Chinese Journal of Gerontology(中国老年学杂志), 2017, 37(4): 1015-1017.
[3] Zhang WB, Ruan QW, Yao F, et al.Comparison of neuropsychiatric symptoms and caregiver burden between Alzheimer's disease and vascular dementia in the middle and late stages[J]. Alzheimer's Disease and Related Diseases(阿尔茨海默病及相关病), 2019, 2(1): 279-283.
[4] Wu JL.The clinical application of aripiprazole[J]. Medical Inform-ation(医学信息), 2018, 31(14): 42-45.
[5] Wang LS.Effects of antipsychotic aripiprazole orally disintegrating tablets in the treatment of 66 cases of Alzheimer’s disease dementia accompanied by mental and behavioral abnormalities[J]. Bingtuan Medicine(兵团医学), 2014, 41(3): 3-4.
[6] Sheng JH, Chen MJ, Gao ZX, et al.Reliability and validity of Alzheimer's disease pathological behavior scale[J]. Journal of Clinical Psychiatry(临床精神医学杂志), 2001(2): 75-77.
[7] Sun R, Zheng LN, Zhu LL, et al.The status and role of modern analytical techniques in the toxicology of traditional Chinese medicine[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2010, 7(10): 613-616.
[8] Hong SZ, Wu H.The application of modern analytical methods and techniques in pharmaceutical analysis[J]. Anhui Chemical Industry(安徽化工), 2018, 44(1): 3-10.
[9] Hamuro A, Saito S.Five Alzheimer's disease cases with refractory behavioural psychological symptoms of dementia treated with blonanserin[J]. Psychogeriatrics, 2010, 10(4): 198-200.
[10] Testad I, Corbett A, Aarsland D, et al.The value of personalized psychosocial interventions to address behavioral and psychological symptoms in people with dementia living in care home settings: a system-atic review.[J]. International Psychogeriatrics, 2014, 26(7): 198-200.
[11] Li GX, Lin Y, Yao MR.Aripiprazole in the treatment of 51 cases of dementia with mental and behavioral symptoms[J]. Medical Herald(医药导报), 2011, 30(10): 1298-1300.
[12] Jin B, Liu H.Comparative efficacy and safety of therapy for the behavioral and psychological symptoms of dementia: a systemic review and Bayesian network meta-analysis.[J]. Journal of Neurology, 2019, 266(10): 2363-2375.
[13] Yunusa I, Alsumali A, Garba AE, et al.Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia: a network meta-analysis.[j]. jama network open, 2019, 2(3): e190828.
[14] Chen PD, Fang LQ.Study on the effects of aripiprazole and risperidone on behavioral disorders and cognitive function in patients with senile dementia[J]. Shanxi Medical Journal(山西医药杂志), 2017, 46(3): 334-336.
[15] Liao QL, Li Y, Deng HY, et al.A comparative study of olanzapine and aripiprazole in the treatment of mental and behavioral symptoms in patients with senile dementia[J]. Chinese National Health and Medical Sciences(中国民康医学), 2015 (1): 9-11.
[16] Li HT.Comparison of the efficacy and safety of aripiprazole and risperidone in the treatment of mental and behavioral symptoms of dementia[J]. China Continuing Medical Education(中国继续医学教育), 2015, 7(4): 213-214.
[17] Luo KY, Chen F, Zhang H, et al.Effects of atypical antipsychotics on glucose metabolism in patients with mental and behavioral symptoms of dementia[J].Medical Journal of Chinese People's Liberation Army(解放军医药杂志), 2017, 29(11): 89-92.
[18] Sevak RJ, Vansickel AR, Stoops WW, et al.Discriminative-stimulus, subject-rated, and physiological effects of metham-phetamine in humans pretreated with aripiprazole.[J]. Journal of clinical psychopharmacology, 2011, 31(4): 470-480.
[19] Wang ZM, Mi WF, Wang XZ, et al.Efficacy and safety of aripiprazole and quetiapine in the treatment of SchizoPhrenia[J].Chinese Journal of Clinical Pharmacology(中国临床药理学杂志), 2012, 28(12): 941-943.
[20] Zhang F, Wang J.Analysis of the clinical efficacy and quality of life of aripiprazole in the treatment of post-schizophrenia depression[J]. Chinese Journal of Neuromedicine(中华神经医学杂志), 2013, 12(5): 521-524.